Dan Dearen

Mr. Dearen is President and Chief Financial Officer of Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a publicly traded medical technology company that manufactures and markets implantable devices to treat overactive bladder (OAB) and stress urinary incontinence (SUI), with sales in 2021 of over $180 million. Mr. Dearen is co-founder of Axonics and has served in his current role for over eight years, during which time the company developed, obtained FDA approval, launched its sacral neuromodulation system to treat OAB, acquired Bulkamid to treat SUI, and completed its IPO in 2018 and four subsequent equity offerings.

Before co-founding Axonics, Mr. Dearen was COO & CFO of Vessix Vascular, a medical device company treating hypertension that was acquired by Boston Scientific in 2012 for $425 million. Previously, he served as Chief Financial Officer of Miraval Holding, Q3DM (acquired by Beckman Coulter), Medication Delivery Devices (acquired by Baxter Healthcare) and was a Principal at Ventana Growth Funds, an international venture capital firm with a portfolio of 53 companies in medical devices, life sciences and healthcare.

Mr. Dearen started his career as a CPA (inactive) in the healthcare group at Ernst & Young in Dallas, Texas. He holds a B.B.A. in Accounting & Business from Southern Methodist University and an M.B.A. from Boston College and completed the Accredited Public Company Director Certification program at the University of California Los Angeles (UCLA).

Mr. Dearen also serves as an Independent Director and Chair of the Audit Committee on the board of Endotronix, Inc. a privately-held digital health and medical technology company dedicated to advancing the treatment of heart failure.